Develops cell therapies for cancer patients with hematologic malignancies and solid tumors.
Jun 2026Revenue $27.0K/yrExpenses $257M/yr
No trendCash runway ≈ 1.5 years from Jun 2026
Figures by year
When will Lyell Immunopharma be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $27.0K and expenses $257M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $36.0K | $269M | −$269M |
| Dec 2024 | $61.0K | $359M | −$359M |
| Dec 2023 | $130K | $247M | −$247M |
| Dec 2022 | $84.7M | $272M | −$187M |
| Dec 2021 | $10.7M | $225M | −$215M |
| Dec 2020 | $7.76M | $220M | −$212M |
| Dec 2019 | $657K | $103M | −$102M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.